Royce & Associates LP grew its stake in Ingevity Corporation (NYSE:NGVT – Free Report) by 7.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,111,158 shares of the company’s stock after acquiring an additional 79,059 shares during the quarter. Ingevity comprises approximately 0.7% of Royce & Associates LP’s investment portfolio, making the stock its 14th biggest position. Royce & Associates LP owned about 3.09% of Ingevity worth $65,758,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Global Retirement Partners LLC acquired a new stake in shares of Ingevity in the 4th quarter worth $27,000. Oakworth Capital Inc. acquired a new stake in shares of Ingevity in the 3rd quarter worth $28,000. Geneos Wealth Management Inc. increased its stake in shares of Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after acquiring an additional 387 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Ingevity in the 2nd quarter worth $46,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of Ingevity in the 3rd quarter worth $62,000. 91.59% of the stock is owned by institutional investors and hedge funds.
Ingevity Stock Down 0.3%
Ingevity stock opened at $66.48 on Tuesday. Ingevity Corporation has a fifty-two week low of $39.74 and a fifty-two week high of $79.29. The company has a debt-to-equity ratio of 27.83, a quick ratio of 0.92 and a current ratio of 1.42. The firm has a 50 day moving average price of $71.43 and a 200 day moving average price of $65.33. The company has a market capitalization of $2.31 billion, a PE ratio of -18.73 and a beta of 1.24.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on NGVT. Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a research report on Tuesday, April 21st. Wells Fargo & Company raised their price objective on Ingevity from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Wall Street Zen raised Ingevity from a “hold” rating to a “strong-buy” rating in a research report on Saturday, May 9th. BMO Capital Markets reissued an “outperform” rating and set a $83.00 price objective on shares of Ingevity in a research report on Monday, March 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and set a $82.00 price objective on shares of Ingevity in a research report on Thursday, February 26th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $80.00.
Read Our Latest Stock Report on Ingevity
Ingevity Profile
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Read More
- Five stocks we like better than Ingevity
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
